SG11201901817SA - Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors - Google Patents

Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors

Info

Publication number
SG11201901817SA
SG11201901817SA SG11201901817SA SG11201901817SA SG11201901817SA SG 11201901817S A SG11201901817S A SG 11201901817SA SG 11201901817S A SG11201901817S A SG 11201901817SA SG 11201901817S A SG11201901817S A SG 11201901817SA SG 11201901817S A SG11201901817S A SG 11201901817SA
Authority
SG
Singapore
Prior art keywords
mamede
coronado
international
siderurgia
nacional
Prior art date
Application number
SG11201901817SA
Inventor
Da Silva Patrício Soares
Tino Rossi
Laszlo Erno Kiss
Alexander Beliaev
Palma Pedro Nuno Leal
Original Assignee
BIAL PORTELA & Cª S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1616201.8A external-priority patent/GB201616201D0/en
Priority claimed from GBGB1713779.5A external-priority patent/GB201713779D0/en
Application filed by BIAL PORTELA & Cª S A filed Critical BIAL PORTELA & Cª S A
Publication of SG11201901817SA publication Critical patent/SG11201901817SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

WO 18/05 685 4 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 March 2018 (29.03.2018) WIP0 I PCT omit VIII °nolo III m Kum H 100 Immo oimIE (10) International Publication Number WO 2018/056854 Al (51) International Patent Classification: A61K 31/40 (2006.01) A61K 31/4196 (2006.01) A61K 31/4025 (2006.01) A61K 31/451 (2006.01) A61K 31/403 (2006.01) A61P 25/00 (2006.01) A61K 31/4188 (2006.01) (21) International Application Number: PCT/PT2017/050022 (22) International Filing Date: 22 September 2017 (22.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1616201.8 23 September 2016 (23.09.2016) GB 1713779.5 29 August 2017 (29.08.2017) GB (71) Applicant: BIAL - PORTELA & Ca, S.A. [PT/PT]; A Av. da Siderurgia Nacional, 4745-457 S. Mamede do Coronado (PT). (72) Inventors: SOARES DA SILVA, Patricio; A Av. da Siderurgia Nacional, 4745-457 S. Mamede do Coronado (PT). ROSSI, Tino; A Av. da Siderurgia Nacional, S. Mamede do Coronado 4745-457 (PT). KISS, Laszlo Er- no; A Av. da Siderurgia Nacional, 4745-457 S. Mamede do Coronado (PT). BELIAEV, Alexander; A Av. da Siderur- gia Nacional, 4745-457 S. Mamede do Coronado (PT). LEAL PALMA, Pedro Nuno; A Av. da Siderurgia Na- cional, 4745-457 S. Mamede do Coronado (PT). (74) Agent: ALVES MOREIRA, Pedro; Rua do Patrocinio N.° 94, 1399-019 Lisboa (PT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) (54) Title: BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS (57) : This invention relates to: (a) compounds of formula (I) (with R 1 to R5, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-13-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.
SG11201901817SA 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors SG11201901817SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1616201.8A GB201616201D0 (en) 2016-09-23 2016-09-23 Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
GBGB1713779.5A GB201713779D0 (en) 2017-08-29 2017-08-29 Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors
PCT/PT2017/050022 WO2018056854A1 (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
SG11201901817SA true SG11201901817SA (en) 2019-04-29

Family

ID=60009687

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901850XA SG11201901850XA (en) 2016-09-23 2017-09-22 Dopamine-b-hydroxylase inhibitors
SG11201901817SA SG11201901817SA (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201901850XA SG11201901850XA (en) 2016-09-23 2017-09-22 Dopamine-b-hydroxylase inhibitors

Country Status (20)

Country Link
US (3) US10975083B2 (en)
EP (2) EP3515917A1 (en)
JP (2) JP2019529460A (en)
KR (2) KR20190076967A (en)
CN (2) CN109715633B (en)
AU (2) AU2017330175B2 (en)
BR (2) BR112019004248A2 (en)
CA (2) CA3037692A1 (en)
CL (2) CL2019000661A1 (en)
CO (2) CO2019002517A2 (en)
IL (2) IL265139B (en)
JO (2) JOP20190049A1 (en)
MA (2) MA46280A (en)
MX (2) MX2019003310A (en)
PE (2) PE20190964A1 (en)
PH (2) PH12019500569A1 (en)
SG (2) SG11201901850XA (en)
TW (2) TWI746644B (en)
UA (2) UA125479C2 (en)
WO (2) WO2018056854A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190049A1 (en) 2016-09-23 2019-03-20 Bial Portela & C? S A Dopamine-?-hydroxylase inhibitors
JOP20190107A1 (en) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
JP7257387B2 (en) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット Spirocyclic compounds and methods of making and using the same
EP3720856A1 (en) 2017-12-04 2020-10-14 BIAL - PORTELA & Cª, S.A. Dopamine-& x392;-hydroxylase inhibitors
GB201908044D0 (en) * 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
CN111675654A (en) * 2020-07-22 2020-09-18 南开大学 Method for synthesizing tetrahydroquinoline compound by taking inert cyclopropane as raw material
CN113354620B (en) * 2021-07-05 2022-03-22 南京桦冠生物技术有限公司 Efficient preparation method of tedizolid intermediate and intermediate thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
ES378317A1 (en) * 1969-04-11 1972-06-01 Robins Co Inc A H A procedure for the preparation of 1-substitute 3-phenylprolrolinins. (Machine-translation by Google Translate, not legally binding)
FR2449689A1 (en) * 1979-02-20 1980-09-19 Logeais Labor Jacques NOVEL CONDENSED PYRROLIDINE OR PIPERIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS
US4728741A (en) * 1985-01-08 1988-03-01 Smithkline Beckman Corporation 1-substituted-2-mercapto benzimidazole compounds and intermediates
JPH04506967A (en) * 1989-07-27 1992-12-03 ジー．ディー．サール　アンド　カンパニー Renal selective products for the treatment of hypertension
JPH07173143A (en) * 1993-12-17 1995-07-11 Wakamoto Pharmaceut Co Ltd New 2-thioxo-4-thiazolidinone derivative and medicine
PT757677E (en) * 1994-04-26 2003-11-28 Syntex Llc BENZOCYCLOHEXYLIMIDAZOLETION DERIVATIVES
US6482982B1 (en) 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
WO2008085008A1 (en) * 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
WO2009015248A1 (en) 2007-07-23 2009-01-29 Synosia Therapeutics Treatment of post-traumatic stress disorder
US20150376198A1 (en) * 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
JOP20190049A1 (en) * 2016-09-23 2019-03-20 Bial Portela & C? S A Dopamine-?-hydroxylase inhibitors

Also Published As

Publication number Publication date
CL2019000661A1 (en) 2019-07-26
US11034695B2 (en) 2021-06-15
WO2018056855A1 (en) 2018-03-29
US20190337950A1 (en) 2019-11-07
UA123071C2 (en) 2021-02-10
CN109715155A (en) 2019-05-03
MA46280A (en) 2019-07-31
US20220017523A1 (en) 2022-01-20
UA125479C2 (en) 2022-03-30
KR20190080864A (en) 2019-07-08
TW201817728A (en) 2018-05-16
CA3036650A1 (en) 2018-03-29
CN109715633B (en) 2022-03-04
AU2017330175A1 (en) 2019-04-04
TW201817713A (en) 2018-05-16
MX2019003352A (en) 2019-09-26
CO2019002517A2 (en) 2019-05-31
AU2017330174A1 (en) 2019-04-04
MA46273A (en) 2019-07-31
CN109715633A (en) 2019-05-03
PE20190964A1 (en) 2019-07-08
US10975083B2 (en) 2021-04-13
CA3037692A1 (en) 2018-03-29
WO2018056854A1 (en) 2018-03-29
KR20190076967A (en) 2019-07-02
SG11201901850XA (en) 2019-04-29
PE20191103A1 (en) 2019-08-23
MX2019003310A (en) 2019-09-26
CO2019002523A2 (en) 2019-05-31
PH12019500568A1 (en) 2019-11-11
JOP20190050A1 (en) 2019-03-20
EP3515433A1 (en) 2019-07-31
JP2019529459A (en) 2019-10-17
BR112019004248A2 (en) 2019-06-04
AU2017330175B2 (en) 2022-02-17
US20200181148A1 (en) 2020-06-11
BR112019004254A2 (en) 2019-06-04
TWI746644B (en) 2021-11-21
IL265139B (en) 2021-08-31
CL2019000662A1 (en) 2019-07-26
PH12019500569A1 (en) 2020-01-20
JP2019529460A (en) 2019-10-17
JOP20190049A1 (en) 2019-03-20
IL265138B (en) 2021-08-31
EP3515917A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
SG11201901817SA (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201808214TA (en) Pyrazolopyrimidine derivatives
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201808686VA (en) Synthesis of indazoles
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201909243TA (en) New bicyclic pyrazole derivatives
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201811804QA (en) Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201907217RA (en) Pharmaceutical combinations for treating cancer
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201809537VA (en) Urea motif containing compounds and derivatives thereof as antibacterial drugs